Список литературы

1. Ferrer I, Martinez A, Blanco R, Dalfo E, Carmona M. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J Neural Transm. 2011;118:821-839.

2. Muller B, Larsen JP, Wentzel-Larsen T, Skeie GO, Tysnes OB; Parkwest Study Group. Autonomic and sensory symptoms and signs in inci­dent, untreated Parkinson's disease: frequent but mild. Mov Disord. 2011;26:65-72.

3. Ellis TD, Cavanaugh JT, Earhart GM, et al. Identifying clinical measures that most accurately reflect the progression of disability in Parkinson disease. Parkinsonism Relat Disord. 2016;25:65-71.

4. Stocchi F, Jenner P, Obeso JA. When do levodopa motor fluctuations first appear in Parkinson's disease? Eur Neurol. 2010;63:257-266.

5. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 2001;56(11 Suppl 5):S1-S88.

6. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's dis­ease: an evidence-based review. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002;58:11-17.

7. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treat­ment of Parkinson disease with motor fluctuations and dyskine­sia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:983-995.

8. National Collaborating Centre for Chronic Conditions (UK). Parkinson's Disease: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. London: Royal College of Physicians (UK); 2006.

9. Oertel WH, Berardelli A, Bloem BR, et al. Chapter 14: early (uncompli­cated) Parkinson's disease. In: Gilhus NE, Barnes MR, Brainin M, eds. European Handbook of Neurological Management: Vol 1. 2nd edition. Chichester: Blackwell; 2010:217-236.

10. Oertel WH, Berardelli A, Bloem BR, et al. Chapter 15: late (compli­cated) Parkinson's disease. In: Gilhus NE, Barnes MR, Brainin M, eds. European Handbook of Neurological Management. Vol 1, 2nd edition. Chichester: Blackwell; 2010:237-267.

11. Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the rec­ommendations of the EFNS/MDS-ES review on therapeutic manage­ment of Parkinson's disease. Eur J Neurol. 2013;20:5-15.

12. Connolly BS, Lang AE. Pharmacological treatment of Parkinson dis­ease: a review. JAMA. 2014;311:1670-1683.

13. Grimes D, Gordon J, Snelgrove B, et al. Canadian Neurological Sciences Federation. Canadian guidelines on Parkinson's disease. Can J Neurol Sci. 2012;39(4 Suppl 4):S1-S30.

14. DANMODIS. Parkinsons sygdom. Klinisk vejledning. 2nd Edition, 2011. http://neuro.dk/wordpress/wp-content/uploads/2012/09/Parkinsons_sygdom_Klinisk_Vejledning_2011.pdf. Accessed

December 7, 2016.

15. SWEMODIS. Svenska riktlinjer for utredning och behandling av Parkinsons sjukdom. 7th Edition, 2014. http://www.swemodis.se/ images/Dokument/Terapird%20Parkinsons%20sjukdom%20ver- sion%207%202014.pdf. Accessed December 7 2016.

16. Referansegruppen for Nasjonal kompetansetjeneste for bevegelses- forstyrrelser. Revidert terapianbefaling ved Parkinsons sykdom. 6th Edition, 2014. https://helse-stavanger.no/seksjon/NKB/Documents/ Nyhetsbulletin/Nyhetsbulletin%202014%20-%20nr.%202.pdf. Accessed December 7, 2016.

17. Reichmann H. Modern treatment in Parkinson's disease, a personal approach. J Neural Transm. 2016;123:73-80.

18. Deutsche Gesellschaft fur Neurologie. Idiopathisches Parkinson- Syndrom.Leitlinienfur Diagnostik undTherapiein der Neurologie. 2016. www.dgn.org/images/red_leitlinien/LL_2016/PDFs_Download/ 030010_LL_langfassung_ips_2016.pdf. Accessed October 17, 2016.

19. Socialstyrelsen. Nationella riktlinjer for vard vid multipel skleros

och Parkinsons sjukdom. Stod for styrning och ledning. Stockholm, 2016. http://www.socialstyrelsen.se/Lists/Artikelkatalog/

Attachments/20392/2016-12-1.pdf. Accessed December 6, 2016.

20. Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P. Parkinson's disease: the non-motor issues. Parkinsonism Relat Disord. 2011;17:717-723.

21. Schrag A, Sauerbier A, Chaudhuri KR. New clinical trials for nonmotor manifestations of Parkinson's disease. Mov Disord. 2015;30:1490-1504.

22. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993;328:176-183.

23. Larsen JP, Boas J, Erdal JE. Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group. Eur J Neurol. 1999;6:539-547.

24. Palhagen S, Heinonen E, Hagglund J, Kaugesaar T, Maki-Ikola O, Palm R; Swedish Parkinson Study Group. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology. 2006;66:1200-1206.

25. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed- start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361:1268-1278.

26. Ahlskog JE, Uitti RJ. Rasagiline, Parkinson neuroprotection, and delayed- start trials: still no satisfaction? Neurology. 2010;74:1143-1148.

27. Clarke CE, Patel S, Ives N, Rick C, Wheatley K, Gray R. Should treatment for Parkinson's disease start immediately on diagno­sis or delayed until functional disability develops? Mov Disord. 2011;26:1187-1193.

28. Rascol O, Hauser RA, Stocchi F, et al. Long-term effects of rasagaline and the natural history of treated Parkinson's disease. Mov Disord. 2016;31:1489-1496.

29. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351:2498-2508.

30. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484-1491.

31. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as ini­tial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61:1044-1053.

32. PD Med Collaborative Group, Gray R, Ives N, et al. Long-term effec­tiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384:1196-1205.

33. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine- agonist treatment in Parkinson's disease. Lancet Neurol. 2007;6:826-829.

34. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67:589-595.

35. Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, et al. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85:840-844.

36. Erga AH, Alves G, Larsen JP, Tysnes OB, Pedersen KF. Impulsive and compulsive behaviors in Parkinson disease: the Norwegian ParkWest Study. J Parkinsons Dis. 2016. doi: 10.3233/JPD-160977.[Epub ahead of print].

37. Rizos A, Sauerbier A, Antonini A, et al. A European multicentre sur­vey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol. 2016;23:1255-1261.

38. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009;72(21 Suppl 4):S1-S136.

39. Chaudhuri KR, Rizos A, Sethi KD. Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery? J Neural Transm. 2013;120:1305-1320.

40. Sawada H, Oeda T, Kuno S, et al. Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. PLoS One. 2010;5:e15298.

41. Ory-Magne F, Corvol JC, Azulay JP, et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology. 2014;82:300-307.

42. Fabbri M, Rosa MM, Abreu D, Ferreira JJ. Clinical pharmacology review of safinamide for the treatment of Parkinson's disease. Neurodegener Dis Manag. 2015;5:481-496.

43. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355:896-908.

44. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's dis­ease. N Engl J Med. 2003;349:1925-1934.

45. Schupbach WM, Chastan N, Welter ML, et al. Stimulation of the sub­thalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry. 2005;76:1640-1644.

46. Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. 2013;368:610-622.

47. Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord. 2006;21(Suppl 14):S290-S304.

48. Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301:63-73.

49. Toft M, Dietrichs E. Medication costs following subthalamic nu­cleus deep brain stimulation for Parkinson's disease. Mov Disord. 2014;29:275-276.

50. Odekerken VJ, Boel JA, Schmand BA, et al. GPi vs STN deep brain stimulation for Parkinson disease: three-year follow-up. Neurology. 2016;86:755-761.

51. Boel JA, Odekerken VJ, Geurtsen GJ, et al. Psychiatric and social out­come after deep brain stimulation for advanced Parkinson's disease. Mov Disord. 2016;31:409-413.

52. Bjerknes S, Skogseid IM, S^hle T, Dietrichs E, Toft M. Surgical site infections after deep brain stimulation surgery: frequency, characteristics and management in a 10-year period. PLoS One. 2014;9:e105288.

53. Toft M, Lilleeng B, Ramm-Pettersen J, et al. Long-term efficacy and mortality in Parkinson's disease patients treated with subthalamic stimulation. Mov Disord. 2011;26:1931-1934.

54. Odin P, Ray Chaudhuri K, Slevin JT, et al. Collective physician per­spectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: consensus from an international survey and discussion program. Parkinsonism Relat Disord. 2015;21:1133-1144.

55. Soulas T, Gurruchaga JM, Palfi S, Cesaro P, Nguyen JP, Fenelon G. Attempted and completed suicides after subthalamic nucleus stimulation for Parkinson's disease. J Neurol Neurosurg Psychiatry. 2008;79:952-954.

56. Weintraub D, Duda JE, Carlson K, et al. Suicide ideation and be­haviours after STN and GPi DBS surgery for Parkinson's disease: re­sults from a randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2013;84:1113-1118.

57. Temel Y, Kessels A, Tan S, Topdag A, Boon P, Visser-Vandewalle V. Behavioural changes after bilateral subthalamic stimulation in ad­vanced Parkinson disease: a systematic review. Parkinsonism Relat Disord. 2006;12:265-272.

58. Xie Y, Meng X, Xiao J, Zhang J, Zhang J. Cognitive changes following bilateral deep brain stimulation of subthalamic nucleus in Parkinson's disease: a meta-analysis. Biomed Res Int. 2016;2016:3596415.

59. Pham U, Solbakk AK, Skogseid IM, et al. Personality changes after deep brain stimulation in Parkinson's disease. Parkinsons Dis. 2015;2015:490507.

60. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005;64:216-223.

61. Nyholm D, Klangemo K, Johansson A. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease. Eur J Neurol. 2012;19:1079-1085.

62. Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infu­sion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double­dummy study. Lancet Neurol. 2014;13:141-149.

63. Fernandez HH, Standaert DG, Hauser RA, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open- label results. Mov Disord. 2015;30:500-509.

64. Buongiorno M, Antonelli F, Camara A, et al. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: the Barcelona registry. Parkinsonism Relat Disord. 2015;21:871-876.

65. Antonini A, Fung VS, Boyd JT, et al. Effect of levodopa-carbidopa in­testinal gel on dyskinesia in advanced Parkinson's disease patients. Mov Disord. 2016;31:530-537.

66. Lang AE, Rodriguez RL, Boyd JT, et al. Integrated safety of levodopa- carbidopa intestinal gel from prospective clinical trials. Mov Disord. 2016;31:538-546.

67. Uncini A, Eleopra R, Onofrj M. Polyneuropathy associated with duode­nal infusion of levodopa in Parkinson's disease: features, pathogenesis and management. J Neurol Neurosurg Psychiatry. 2015;86:490-495.

68. Antonini A, Isaias IU, Rodolfi G, et al. A 5-year prospective assess­ment of advanced Parkinson disease patients treated with subcu­taneous apomorphine infusion or deep brain stimulation. J Neurol. 2011;258:579-585.

69. Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord. 2002;17:1235-1241.

70. Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutane­ous apomorphine therapy improves dyskinesias in Parkinson's dis­ease: a prospective study using single-dose challenges. Mov Disord. 2005;20:151-157.

71. Drapier S, Gillioz AS, Leray E, et al. Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications. Parkinsonism Relat Disord. 2012;18:40-44.

72. Drapier S, Eusebio A, Degos B, et al. Quality of life in Parkinson's dis­ease improved by apomorphine pump: the OPTIPUMP cohort study. J Neurol. 2016;263:1111-1119.

73. Borgemeester RW, Drent M, van Laar T. Motor and non-motor out­comes of continuous apomorphine infusion in 125 Parkinson's dis­ease patients. Parkinsonism Relat Disord. 2016;23:17-22.

74. Martinez-Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multi­center comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov Disord. 2015;30:510-516.

75. Volkmann J, Albanese A, Antonini A, et al. Selecting deep brain stim­ulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. J Neurol. 2013;260:2701-2714.


76. Odin P, Nyholm D. Patient selection for continuous dopaminer­gic stimulation therapy. In: Aquilonius S-M, Mouradian MM, eds. Parkinson's Disease. Role of Continuous Dopaminergic Stimulation. Crowthorne: ESP Bioscience; 2012:162-172.

  1. Collins MW, Iverson GL, Gaetz M, Lovell MR (2006). "Sport-related concussion" . In Zasler ND, Katz DI, Zafonte RD. Brain Injury Medicine: Principles and Practice.)

  2. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3721093/?report=reader#!po=7.89474

  3. http://www.sportmedicine.ru/brain_conc.php

  4. Lee H, Wintermark M, Gean AD, Ghajar J, Manley GT, Mukherjee P., Focal lesions in acute mild traumatic brain injury and neurocognitive outcome: CT versus 3T MRI. J Neurotrauma. 2008 Sep;25(9):1049-56. doi: 10.1089/neu.2008.0566.

  5. Neurology and trauma/[edited by] Randolph W. Evans. — 2nd ed. 2006. Заказ в Google Книги

  6. Shenton ME, Hamoda HM, Schneiderman JS, Bouix S, Pasternak O, Rathi Y, Vu MA, Purohit MP, Helmer K, Koerte I, Lin AP, Westin CF, Kikinis R, Kubicki M, Stern RA, Zafonte R. A review of magnetic resonance imaging and diffusion tensor imaging findings in mild traumatic brain injury. Brain Imaging Behav. 2012

  7. Тарас Шелестюк. 12 раундов к цели / Тарас Шелестюк, Станислав Бондаренко. К.: Саммит-Книга, 2013. -264 с. Электронная книга в Google Книги


Использованная литература

  1. Еганян Р.А. Диета и статины в профилактике ишемической болезни сердца (литературный обзор), Русский медицинский журнал

  2. Рекомендации Европейского общества кардиологов и Европейского общества атеросклероза по лечению дислипидемий. Рациональная Фармакотерапия в Кардиологии 2012; приложение №1

  3. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8(5):453.

  4. Bowman TS, Sesso HD, Ma J, Kurth T, Kase CS, Stampfer MJ, Gaziano JM. Cholesterol and the risk of ischemic stroke. Stroke. 2003;34: 2930–2934.

  5. Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch Intern Med. 2003;163(6):669.

  6. http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm

  7. http://www.uptodate.com/contents/statins-actions-side-effects-and-administration

  8. http://www.uptodate.com/contents/treatment-of-lipids-including-hypercholesterolemia-in-primary-prevention

  9. Macedo AF, Taylor FC, Casas JP, Adler A, Prieto-Merino D, Ebrahim S. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med. 2014 Mar 22;12:51. doi: 10.1186/1741-7015-12-51

  10. Mihaylova B, Emberson J. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Cholesterol Treatment Trialists' (CTT) Collaborators, Lancet. 2012 Aug;380(9841):581-90. Epub 2012 May 17

  11. Sacco RL, Benson RT, Kargman DE, Boden-Albala B, Tuck C, Lin IF, Cheng JF, Paik MC, Shea S, Berglund L. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA. 2001;285:2729 –2735.

  12. Stone NJ, et al. 2013 ACC/AHA Blood Cholesterol Guideline

  13. West of Scotland Coronary Prevention Study. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS) // Circulation. 1998. Vol. 97. P. 1440–1445.

  14. Wilson PW, Hoeg JM, Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis. N Engl J Med. 1997;337:516 –522.

  15. Zhang X, Patel A, Horibe H, Wu Z, Barzi F, Rodgers A, MacMahon S, Woodward M. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol. 2003;32:563–572.

  16. Horton JD, Cohen JC, Hobbs HH, PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009 Apr;50 Suppl:S172-7. Epub 2008 Nov 19.